Search
Levoketoconazole
go.drugbank.com/drugs/DB05667Approved[A244078, A244083] [Ketoconazole] has been used both on- and off-label to treat CS due to its ability to inhibit cortisol production.
Dimazole
go.drugbank.com/drugs/DB13858ApprovedWithdrawnIt was withdrawn in Franch in 1972 due to neuropsychiatric reactions.
Eflapegrastim
go.drugbank.com/drugs/DB15001ApprovedInvestigational[L43135] Eflapegrastim is a form of recombinant human G-CSF comprising a human G-CSF analog coupled to the Fc fragment of human IgG4 via a polyethylene glycol linker.
Capmatinib
go.drugbank.com/drugs/DB11791ApprovedInvestigational[A199122] Aberrant c-Met activation - via mutations, amplification, and/or overexpression - is known to occur in many types of cancer, and leads to overactivation of multiple downstream signaling pathways
Difluocortolone
go.drugbank.com/drugs/DB09095ApprovedWithdrawnDifluocortolone is a potent topical corticosteroid. It is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.
Doxazosin
go.drugbank.com/drugs/DB00590ApprovedInvestigationalDoxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include Prazosin, Terazosin, Tamsulosin, and Alfuzosin. Because of its long-lasti...
Thenalidine
go.drugbank.com/drugs/DB04826ApprovedWithdrawnWithdrawn from the Canadian, US, and UK markets in 1963 due to concerns involving neutropenia.
Rapacuronium
go.drugbank.com/drugs/DB04834ApprovedWithdrawnRapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.
Tianeptine
go.drugbank.com/drugs/DB09289InvestigationalTianeptine is a drug used primarily in the treatment of major depressive disorder and has been studied in the treatment of irritable bowel syndrome (IBS) . Structurally, it is classified as a tricyclic antidepressant (TCA), however, it p...
Oseltamivir
go.drugbank.com/drugs/DB00198ApprovedInvestigationalNotably, in 2017, the World Health Organization downgraded oseltamivir from its essential medicines list from a "core" drug to a "complementary" drug, due to limited cost-effectiveness. … [A179962, A179965, A179968] Due to the risk of adverse effects such as nausea, vomiting, psychiatric effects and renal adverse events in adults and vomiting in children, the harms are generally considered